Abstract
Avdoralimab (IPH5401) is a monoclonal antibody that inhibits the binding of the complement factor C5a to the receptor C5aR1. Preclinical analysis revealed that inhibition of C5a/C5aR1 axis limited myeloid derived suppressor cells (MDSCs) and increased CD8 T-cell tumor infiltration, promoting tumor reduction and limiting metastatic potential. Furthermore, the combined use of C5a/C5aR1 inhibition and anti-PD(L)1 therapy (IO) was shown to be superior to each modality alone in terms of reducing tumor volume and improving survival in several preclinical murine models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
